PHILADELPHIA, PA — March 27, 2002 — GlaxoSmithKline announced that Paxil CR, a new, controlled-release formulation of a leading anxiolytic-antidepressant, Paxil® (paroxetine hydrochloride), will be available to patients by the end of April.
Paxil CR is approved by the U.S. Food and Drug Administration for the treatment of major depressive disorder and panic disorder.
Paxil CR incorporates new, controlled-release, Geomatrix technology licensed from SkyePharma PLC. The tablet is in a multi-layered formulation that controls dissolution and absorption of the drug in the body. Paxil CR offers flexible dosing, and will be available in three dosing strengths: 12.5 mg, 25 mg and 37.5 mg.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!